LQDA - Liquidia Technologies, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.8700
-0.1300 (-2.60%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close5.0000
Open5.0800
Bid0.0000 x 2900
Ask0.0000 x 1300
Day's Range4.8000 - 5.2500
52 Week Range2.6500 - 20.0500
Volume169,172
Avg. Volume222,831
Market Cap137.487M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Liquidia seeks pivotal FDA approval for lead drug
    American City Business Journals

    Liquidia seeks pivotal FDA approval for lead drug

    Morrisville-based Liquidia has submitted its lead drug asset for potential approval by the U.S. Food and Drug Administration.

  • Will Liquidia Continue to Surge Higher?
    Zacks

    Will Liquidia Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Liquidia.

  • Liquidia nets $22.4 million as it moves forward with lead drug
    American City Business Journals

    Liquidia nets $22.4 million as it moves forward with lead drug

    Ahead of a planned regulatory application early next year, a Triangle drugmaker has brought in more than $22 million.

  • MarketWatch

    Liquidia Technologies stock soars after Wedbush says private placement gives company runway through Q4 2020

    Shares of Liquidia Technologies Inc. , a Durham, N.C.-based biotech, soared more than 70% Thursday before paring their gains, after Wedbush reiterated an outperform rating on the stock and said a $22.4 million fundraising will give the company the runway to keep going through the fourth quarter of 2020. The company said it sold 7.2 million shares at $3.13 a share in a private placement. Liquidia is aiming to leverage its proprietary Print technology to improve the clinical profile of approved active pharmaceutical ingredients, or APIs. The company's lead candidate called LIQ861 is a dry powder formulation of inhaled treprostinil to treat pulmonary arterial hypertension, or PAH. "In our view, LIQ861 has the potential to improve the therapeutic profile of treprostinil in treating PAH by safely delivering higher doses into the lung," Wedbush analysts led by Liana Moussatos wrote in a note to clients. The company is expecting to file a new drug application for the treatment in the first quarter of 2020. A second product candidate, LIQ865, a treatment for post-operative pain, is expected to enter phase 2 trials in 2020, said the note. Shares were last up 43% and have fallen 77% in the year to date, while the S&P 500 has gained 29%. Company plans to initiate a Phase 2 study in 2020.

  • Is Liquidia Technologies, Inc. (LQDA) A Good Stock To Buy?
    Insider Monkey

    Is Liquidia Technologies, Inc. (LQDA) A Good Stock To Buy?

    As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the third quarter. We get to see hedge funds' thoughts towards the market and […]

  • Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Misses Revenue Estimates

    Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -38.46% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Liquidia Technologies, Inc. (LQDA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
    Zacks

    Liquidia Technologies, Inc. (LQDA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

    Liquidia Technologies, Inc. (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Is Liquidia Technologies (NASDAQ:LQDA) Using Too Much Debt?
    Simply Wall St.

    Is Liquidia Technologies (NASDAQ:LQDA) Using Too Much Debt?

    Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

  • Could Liquidia Technologies, Inc.'s (NASDAQ:LQDA) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could Liquidia Technologies, Inc.'s (NASDAQ:LQDA) Investor Composition Influence The Stock Price?

    Every investor in Liquidia Technologies, Inc. (NASDAQ:LQDA) should be aware of the most powerful shareholder groups...

  • Hedge Funds Have Never Been This Bullish On Liquidia Technologies, Inc. (LQDA)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Liquidia Technologies, Inc. (LQDA)

    Is Liquidia Technologies, Inc. (NASDAQ:LQDA) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […]